Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives (Q34426072)

2 August 2017

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

1

Anthony H V Schapira

1 reference

2 August 2017

Charles Warren Olanow

series ordinal

2

object named as

C Warren Olanow

1 reference

2 August 2017

J Timothy Greenamyre

3

1 reference

2 August 2017

Erwan Bezard

series ordinal

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

18 June 2014

1 reference

2 August 2017

1 reference

2 August 2017

384

1 reference

2 August 2017

9942

1 reference

2 August 2017

545-555

1 reference

Epidemiology of Parkinson's disease

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Therapeutic approaches to preventing cell death in Huntington disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Molecular and clinical prodrome of Parkinson disease: implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

An introduction to adaptive designs and adaptation in CNS trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Recent developments in biomarkers in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Huntington's disease: from molecular pathogenesis to clinical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Neuroprotection for Huntington's disease: ready, set, slow

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Neurodegenerative processes in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Nucleic Acid-Based Therapy Approaches for Huntington's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Mitochondria in the aetiology and pathogenesis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

The Sir2 family of protein deacetylases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Parkinson's disease, insulin resistance and novel agents of neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Exenatide and the treatment of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

The pathways of mitophagy for quality control and clearance of mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Molecular mechanisms and potential therapeutical targets in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Mitochondrial defect in Huntington's disease caudate nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Autophagy modulation as a potential therapeutic target for diverse diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Calcium, ageing, and neuronal vulnerability in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

'Rejuvenation' protects neurons in mouse models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

alpha-Synuclein is phosphorylated in synucleinopathy lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Chaperone-mediated autophagy markers in Parkinson disease brains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

alpha-Synuclein locus triplication causes Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

In vivo demonstration that alpha-synuclein oligomers are toxic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Is Parkinson's disease a prion disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Are synucleinopathies prion-like disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Prion-like acceleration of a synucleinopathy in a transgenic mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Fighting neurodegeneration with rapamycin: mechanistic insights

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Lewy-body formation is an aggresome-related process: a hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Activation of the unfolded protein response in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Sustained translational repression by eIF2α-P mediates prion neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Exosome-mediated delivery of siRNA in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Recent advances in RNA interference therapeutics for CNS diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Gene therapy for misfolding protein diseases of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Antisense oligonucleotides: treating neurodegeneration at the level of RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Intrabodies as neuroprotective therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Treatment of Parkinson's disease with trophic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Cytochrome C and caspase-9 expression in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

Huntingtin-interacting protein 1-mediated neuronal cell death occurs through intrinsic apoptotic pathways and mitochondrial alterations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961010-2

7 January 2021

10.1016/S0140-6736(14)61010-2

Identifiers

DOI

1 reference

2 August 2017

1 reference